Abstract
Alzheimers disease (AD) is the most common form of dementia in the elderly with more than 26 million people worldwide living with the disease. Besides the main neuropathological hallmarks of AD, provoked by the accumulation of amyloid-β (Aβ) and tau hyperphosphorylation, other cells and cellular systems such as microglia and the neurovascular unit establishing the blood-brain-barrier (BBB) have been implicated to play a role in AD etiopathology. Insulating the brain from the blood stream, the BBB facilitates supply and disposal of nutrients and metabolites by the expression of transporters and transcytotic receptors at the polarized endothelial cell (EC) surface. Recently, several proteins involved in Aβ transport across the BBB have been identified in in vitro and in vivo studies. In this review, we summarize recent evidence of receptor- and transporter-mediated Aβ clearance across the BBB. Furthermore, we discuss the models used to identify and characterize Aβ transport across the BBB in regard to barrier properties and their suitability for experimental investigation of Aβ clearance mechanisms at an EC barrier.
Keywords: Alzheimer’s disease, Amyloid-β, Blood-Brain-Barrier, Transmembrane receptor, ABC transporter, clearance, transport, transcytosis.
Current Alzheimer Research
Title: Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Volume: 7 Issue: 7
Author(s): T. Pflanzner, C. R. Kuhlmann and C. U. Pietrzik
Affiliation:
Keywords: Alzheimer’s disease, Amyloid-β, Blood-Brain-Barrier, Transmembrane receptor, ABC transporter, clearance, transport, transcytosis.
Abstract: Alzheimers disease (AD) is the most common form of dementia in the elderly with more than 26 million people worldwide living with the disease. Besides the main neuropathological hallmarks of AD, provoked by the accumulation of amyloid-β (Aβ) and tau hyperphosphorylation, other cells and cellular systems such as microglia and the neurovascular unit establishing the blood-brain-barrier (BBB) have been implicated to play a role in AD etiopathology. Insulating the brain from the blood stream, the BBB facilitates supply and disposal of nutrients and metabolites by the expression of transporters and transcytotic receptors at the polarized endothelial cell (EC) surface. Recently, several proteins involved in Aβ transport across the BBB have been identified in in vitro and in vivo studies. In this review, we summarize recent evidence of receptor- and transporter-mediated Aβ clearance across the BBB. Furthermore, we discuss the models used to identify and characterize Aβ transport across the BBB in regard to barrier properties and their suitability for experimental investigation of Aβ clearance mechanisms at an EC barrier.
Export Options
About this article
Cite this article as:
Pflanzner T., R. Kuhlmann C. and U. Pietrzik C., Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499066
DOI https://dx.doi.org/10.2174/156720510793499066 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Amyloid Formation in Surfactants and Alcohols: Membrane Mimetics or Structural Switchers?
Current Protein & Peptide Science Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Modulatory Activity of Soluble Beta Amyloid on HPA Axis Function in Rats
Current Pharmaceutical Design Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model
Current Alzheimer Research Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets